Skip to content
DataLookout
Menu

NCT07895043

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer

StatusNot Yet Recruiting
PhasePhase 2
SponsorAbbVie
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Timeframe: Up to approximately 4 years
Number of Participants with Adverse Events (AEs)
Timeframe: Up to approximately 4 years

Secondary (6)

Progression-Free Survival (PFS) as Assessed by BICR Per RECIST v1.1
Disease Control Rate (DCR) as Assessed by BICR
Duration of Response (DoR) as Assessed by BICR
Overall Survival
Percentage of Participants Achieving Molecular Response (≥50% Reduction)
Show 1 moreShow less
Percentage of Participants Achieving Complete Molecular Clearance (100% Reduction)

Arms and interventions

ABBV-706 Dose A + Alveltamig + AtezolizumabExperimental

Participants will receive ABBV-706 dose A in combination with alveltamig and atezolizumab during the safety lead-in and dose expansion periods.

ABBV-706 Dose B + Alveltamig + AtezolizumabExperimental

Participants will receive ABBV-706 dose B in combination with alveltamig and atezolizumab during the safety lead-in and dose expansion periods.

Drugs: Alveltamig, Atezolizumab, ABBV-706